CEL-SCI CORPORATION
VIENNA, VA · CIK 0000725363 · Biotech · Private
Cellular immunotherapies based on proprietary immune cell engineering platforms
cel.bio →- Grants
- $1.5M
- 2 awards
- Sector median: 1
- Raised
- $1.1M
- 3 Form D · Jul 2018
- 99 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 19
- 0 granted · 19 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2016201720182019
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $1,000,000 | |
| Private capital raised | Form D · SEC | $1,510,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Preclinical studies of PG70 LEAPS peptide vaccines for rheumatoid arthritis | $806,505 | |
| Private capital raised | Form D · SEC | $78,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Preclinical studies of PG70 LEAPS peptide vaccines for rheumatoid arthritis | $691,469 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1607 | XenoTherapeutics Corp | — | $1.3M |
| 1608 | RIBO-THERAPEUTICS LLC | — | — |
| 1609 | Yuva Biosciences, Inc. | — | $1.1M |
| 1610 | CEL-SCI CORPORATION | — | $1.1M |
| 1611 | CELL ORIGINS, LLC | — | — |
| 1612 | GATC HEALTH CORP | — | $981K |
| 1613 | DIVERSE BIOTECH, INC. | — | $669K |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Bruno BailavoineDirector
- Bruno BaillavoineDirector
- John CiprianoExecutive Officer
- Alexander EsterhazyDirector
- Geert KerstenDirector · Executive Officer
- Patricia PrichepExecutive Officer
- Eyal TalorExecutive Officer
- Robert WatsonDirector
- Peter YoungDirector
- Daniel ZimmermanExecutive Officer
Patents
- NOVEL PEPTIDES FOR VACCINATION AND TREATMENT OF 2019-nCoV INFECTIONSapplication
- Peptides And Conjugates For Treatment Of Arthritisapplication
- NOVEL PEPTIDES FOR VACCINATION AND TREATMENT OF 2019-nCoV INFECTIONSapplication
- NOVEL PEPTIDES FOR VACCINATION AND TREATMENT OF 2019-nCoV INFECTIONSapplication
- Peptides And Conjugates For Treatment Of Arthritisapplication
- Methods Of Preparation And Composition Of Peptide Constructs Useful For Treatment Of Rheumatoid Arthritisapplication
- Method For Inducing An Immune Response And Formulations Thereofapplication
- Method For Inducing An Immune Response For Treatment Of Cancer And Autoimmune Diseases Or Conditionsapplication
- Method For Inducing An Immune Response Against Avian, Swine, Spanish, H1N1, H5N9 Influenza Viruses And Formulations Thereofapplication
- Compositions And Methods For Modulating Immunogenic Responses By Activating Dendritic Cellsapplication
- Methods Of Preparation And Composition Of Peptide Constructs Useful For Treatment Of Rheumatoid Arthritisapplication
- A Method For Modulating Hla Class II Tumor Cell Surface Expression With A Cytokine Mixtureapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.